Skip to main content
Free trial

Analyze this stock with AI

Ask AI to research recent events and build a visual report.

Tell your AI:

“Help me set up FinLab and analyze NBIX Neurocrine Biosciences, Inc.: https://finlab.finance/en/setup?stock=NBIX”

Run AI in browser

NBIX

Neurocrine Biosciences, Inc. Healthcare As of 2026-06-18
Quality Above avg
Valuation Expensive
Risk Moderate
Active signals Active Filed revenue acceleration
158.29 Close (USD)
+23.8% 60-day
  • Quality is above average. Operating margin sits near the 80th percentile. TTM ROE is about 19.6%.
  • Valuation is expensive. TTM P/E is in the 78th percentile, above most peers.
  • Recent volatility is moderate. 60-day annualized volatility is near the 54th percentile. Average 20-day dollar volume is about $187.6M.
  • Signals are active now. Filed revenue acceleration currently holds; the tables below show what followed in this stock’s own history.

Factor profile

Factor radar Weak Valuation
36
ValuationQualityGrowthMomentumRisk / liquidity

Valuation

Indicators in this group are ranked by market percentile; lower valuation and volatility are better.

36 Weak
TTM P/E 24.39
Pricey
Price / book 4.67
Expensive
Free-cash-flow yield (%) 5.23
Good

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Filed revenue acceleration

Active · now 28.591560971565944%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

11 historical occurrences (since 2018-04-30)
Average forward return after Filed revenue acceleration。20-day: Win 45.5%, Sample 11, Median -2.61%, Excess +2.24%, Beat mkt rate 63.6%；60-day: Win 50%, Sample 10, Median +0.6%, Excess +0.66%, Beat mkt rate 50%；120-day: Win 55.6%, Sample 9, Median +10.78%, Excess +6.33%, Beat mkt rate 55.6%

120 days after: historical avg +8.95%

20-day +0.47%
60-day +2.13%
120-day +8.95%
20-day
60-day
120-day
Win
45.5%
50%
55.6%
Sample
11
10
9
Median
-2.61%
+0.6%
+10.78%
Excess
+2.24%
+0.66%
+6.33%
Beat mkt rate
63.6%
50%
55.6%

Over 9 occurrences, 120-day forward avg gained 8.95%, beat the market by 6.33 pts; win rate 55.6%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 You are here164+13% +17% 77.4% -0.3%
20-40 355+10% +9% 68.5% -11.1%
40-60 203+17.8% +14.4% 75.9% +5.9%
60-80 77+3.5% -0.7% 45.5% -8.2%
80-100 62+1.6% +1.5% 67.7% -12%

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 24.39, placing it in the 10.5 own-history percentile, inside the 0-20 bucket.

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
Now
+3.9%
Win rate 50.1% Excess -5.1%
355d
+6.1%
Win rate 72.8% Excess +1.4%
228d
-4.7%
Win rate 12.9% Excess -8.6%
62d
60-day momentum down
+7.2%
Win rate 52.5% Excess -0.5%
181d
+17.5%
Win rate 83.9% Excess +12.1%
155d
Insufficient data
(0d)

Currently in “Cheap (own-history bottom third) × 60-day momentum up”: across 355 historical days, 120-day forward avg gained 3.9%, win rate 50.1%, lagged the market by 5.1%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 94,737 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.40%, a 58.3% positive-return rate, and +3.10 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

23 times historically; 60-day forward avg +1.63%, win rate 52.4%, beating the market by -0.97 pts on average.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

17 times historically; 60-day forward avg +5.84%, win rate 64.7%, beating the market by +0.16 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

18 times historically; 60-day forward avg +2.8%, win rate 62.5%, beating the market by -0.39 pts on average.

Free trial

Analyze this stock with AI

Ask AI to research recent events and build a visual report.

Tell your AI:

“Help me set up FinLab and analyze NBIX Neurocrine Biosciences, Inc.: https://finlab.finance/en/setup?stock=NBIX”

Run AI in browser

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.